HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Oliver Grottke Selected Research

Prothrombin (Factor II)

10/2021Reversing Rivaroxaban Anticoagulation as Part of a Multimodal Hemostatic Intervention in a Polytrauma Animal Model.
11/2020Sufficient Thrombin Generation Despite 95% Hemodilution: An In Vitro Experimental Study.
1/2019Prothrombin Complex Concentrate-induced Disseminated Intravascular Coagulation Can Be Prevented by Coadministering Antithrombin in a Porcine Trauma Model.
1/2019Evaluation of combined idarucizumab and prothrombin complex concentrate treatment for bleeding related to dabigatran in a lethal porcine model of double trauma.
11/2017Reversing Dabigatran Anticoagulation with Prothrombin Complex Concentrate versus Idarucizumab as Part of Multimodal Hemostatic Intervention in an Animal Model of Polytrauma.
1/2016Therapy with activated prothrombin complex concentrate is effective in reducing dabigatran-associated blood loss in a porcine polytrauma model.
1/2016Hemostatic Therapy Using Tranexamic Acid and Coagulation Factor Concentrates in a Model of Traumatic Liver Injury.
12/2015Prothrombin Complex Concentrate Is Effective in Treating the Anticoagulant Effects of Dabigatran in a Porcine Polytrauma Model.
4/2015Reversal of dabigatran anticoagulation ex vivo: Porcine study comparing prothrombin complex concentrates and idarucizumab.
2/2014Prothrombin complex concentrates and a specific antidote to dabigatran are effective ex-vivo in reversing the effects of dabigatran in an anticoagulation/liver trauma experimental model.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Oliver Grottke Research Topics

Disease

37Wounds and Injuries (Trauma)
01/2022 - 01/2009
33Hemorrhage
05/2022 - 03/2010
5Multiple Trauma (Multiple Injuries)
10/2021 - 12/2015
5Hypothermia
01/2015 - 06/2007
4COVID-19
10/2021 - 01/2021
3Atrial Fibrillation
05/2022 - 04/2016
3Respiratory Distress Syndrome (Acute Respiratory Distress Syndrome)
06/2021 - 01/2017
3Thrombosis (Thrombus)
03/2021 - 11/2013
3Hemorrhagic Shock
11/2020 - 01/2018
3Disseminated Intravascular Coagulation
01/2019 - 08/2011
3Thromboembolism
11/2016 - 01/2013
2Critical Illness (Critically Ill)
06/2021 - 01/2021
2Heart Failure
03/2021 - 01/2020
2Sepsis (Septicemia)
11/2019 - 01/2017
2Shock
08/2019 - 06/2007
2Hemolysis
01/2019 - 09/2015
2Traumatic Brain Injuries (Traumatic Brain Injury)
03/2018 - 01/2009
2Stroke (Strokes)
09/2016 - 01/2009
2Hemophilia A (Haemophilia)
01/2015 - 03/2010
1Cerebral Hemorrhage
05/2022
1Intracranial Hemorrhages (Intracranial Hemorrhage)
05/2022
1Inflammation (Inflammations)
01/2022
1Traumatic Shock
01/2022
1Pulmonary Hypertension
10/2021
1Tics (Tic)
08/2021
1Embolism (Embolus)
06/2021
1Postpartum Hemorrhage
02/2020
1End Stage Liver Disease
02/2020
1Afibrinogenemia (Fibrinogen Deficiency)
02/2020
1Infections
12/2019
1Contusions
01/2019
1Postoperative Hemorrhage
01/2019
1Hip Fractures (Intertrochanteric Fractures)
01/2019
1Hypoxia (Hypoxemia)
11/2016
1Ischemic Stroke
04/2016
1Atherosclerosis
03/2015
1Acute-Phase Reaction
10/2014
1Coma (Comas)
06/2011

Drug/Important Bio-Agent (IBA)

19AnticoagulantsIBA
05/2022 - 01/2013
14Prothrombin (Factor II)IBA
10/2021 - 12/2010
12Fibrinogen (Factor I)FDA Link
10/2021 - 01/2010
12DabigatranFDA Link
01/2019 - 02/2014
11idarucizumabIBA
08/2021 - 02/2014
8ThrombinFDA Link
11/2020 - 10/2011
7Vitamin KFDA Link
05/2022 - 09/2016
7Blood Coagulation Factors (Coagulation Factor)IBA
11/2020 - 06/2007
5prothrombin complex concentrates (PPSB)IBA
01/2020 - 02/2014
4Hemostatics (Antihemorrhagics)IBA
10/2021 - 04/2014
4Tranexamic Acid (AMCA)FDA Link
10/2021 - 04/2015
3AntidotesIBA
01/2019 - 02/2014
3recombinant FVIIa (rFVIIa)FDA Link
01/2015 - 03/2010
2RivaroxabanIBA
01/2022 - 10/2021
2apixabanIBA
01/2022 - 08/2019
2Factor Xa InhibitorsIBA
10/2021 - 08/2019
2PRT064445IBA
08/2021 - 08/2019
2InterleukinsIBA
05/2021 - 09/2015
2von Willebrand FactorIBA
01/2019 - 09/2015
2AntithrombinsIBA
01/2019 - 09/2014
2FibrinIBA
04/2015 - 04/2014
2TachoSilIBA
04/2014 - 11/2011
2CollagenIBA
04/2014 - 11/2011
1Heparin (Liquaemin)FDA LinkGeneric
01/2022
1Heparin Lyase (heparin lyase)IBA
01/2022
1Heparitin Sulfate (Heparan Sulfate)IBA
01/2022
1Bicarbonates (Hydrogen Carbonate)IBA
10/2021
1Alanine Transaminase (SGPT)IBA
10/2021
1Hemoglobins (Hemoglobin)IBA
10/2021
11,25-dihydroxyvitamin DIBA
12/2019
125-hydroxyvitamin DIBA
12/2019
1LipopolysaccharidesIBA
11/2019
1Warfarin (Coumadin)FDA LinkGeneric
01/2019
1ErythropoietinFDA Link
11/2016
1XenonIBA
11/2016
1Pharmaceutical PreparationsIBA
09/2016
1Antifibrinolytic Agents (Antifibrinolytics)IBA
01/2016
1hemoglobin ASIBA
09/2015
1estropipate (Ogen)FDA LinkGeneric
04/2015
1Macrophage Migration-Inhibitory FactorsIBA
03/2015
1CytokinesIBA
03/2015
1ChemokinesIBA
03/2015
1Carbon MonoxideIBA
06/2011

Therapy/Procedure

13Therapeutics
05/2022 - 04/2014
5Extracorporeal Membrane Oxygenation
10/2021 - 01/2017
5Resuscitation
08/2021 - 12/2012
3Heart-Assist Devices
01/2020 - 01/2018
3Anticoagulation Reversal
11/2016 - 12/2015
1Palliative Care (Palliative Therapy)
05/2022
1Positive-Pressure Respiration (Positive End-Expiratory Pressure)
10/2021
1Extracorporeal Circulation
03/2021
1Artificial Respiration (Mechanical Ventilation)
01/2021
1Transplantation
01/2020
1Hemofiltration
11/2019
1Length of Stay
01/2019
1Combined Modality Therapy
11/2017
1Ligation
01/2017
1Punctures
01/2017
1Cardiopulmonary Bypass (Heart-Lung Bypass)
04/2015
1Secondary Prevention
04/2014
1Hemodilution
04/2014
1Operative Surgical Procedures
03/2013